It is possible that certain immunogenic nonmelanoma cancers (such as renal cell carcinoma and triple-negative breast cancer) or specific subsets of populations (such as sarcomatoid renal cell carcinoma or squamous cell lung cancer with high tumor mutational burden and low PD-L1) may have survival benefit with the combination over single-agent nivolumab, although this remains to be determined. This evidence concerns the gene CD274 and hereditary clear cell renal cell carcinoma.